Estimated unadjusted cumulative incidence did not differ between long-term care residents who were deprescribed or continued antihypertensives
TUESDAY, Dec. 3, 2024 (HealthDay News) — Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) or stroke in long-term care residents, according to a study published online Nov. 25 in JAMA Network Open.
Michelle C. Odden, Ph.D., from Stanford University in California, and colleagues compared the incidence of hospitalization for MI or stroke among long-term care residents who are deprescribed or continue antihypertensive therapy. The analysis included 13,096 U.S. veterans residing in long-term care (Oct. 1, 2006, to Sept. 30, 2019) taking at least one antihypertensive medication.
The researchers found that 17.8 percent of veterans were deprescribed antihypertensive medication during a period of 12 weeks. Over two years, a similar estimated unadjusted cumulative incidence of stroke or MI hospitalization was seen for residents who were and were not deprescribed antihypertensives (11.2 versus 8.8 percent). In fully adjusted models, the per-protocol analysis results showed no association of antihypertensive deprescribing with MI or stroke hospitalization (hazard ratio, 0.93; 95 percent confidence interval, 0.70 to 1.26).
“A randomized clinical trial would help address concerns about unmeasured confounding but could be challenging to implement in this complex population,” the authors write. “More research is needed on deprescribing methods and potential consequences to inform this growing practice and inform patient and clinician shared decision-making.”
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout